Evaluation of the Antipruritic Effects of Topical Pimecrolimus in Non-Atopic Prurigo Nodularis: Results of a Randomized, Hydrocortisone-Controlled, Double-Blind Phase II Trial

Dorothee Siepmann, Tobias Lotts, Christine Blome, Matthias Braeutigam, Ngoc Quan Phan, Trude Butterfaß‐Bahloul, Matthias Augustin, Thomas A. Luger, Sonja Ständer

Dermatology · 2013 · 66 citations · 19 references

Concepts

Abstract

<b><i>Background:</i></b> In the treatment of atopic dermatitis, pimecrolimus has high antipruritic effects. <b><i>Objective:</i></b> To investigate the efficacy of 1% pimecrolimus cream in comparison to 1% hydrocortisone cream in non-atopic prurigo nodularis (PN). <b><i>Methods:</i></b> A randomized, controlled, double-blind study with intraindividual randomization was done in 30 patients (17 females, 13 males; mean age 58.5 years) with PN. <b><i>Results:</i></b> Pruritus intensity decreased significantly (p < 0.001) on both treated sides as early as after 10 days of treatment; scratch lesions improved (p < 0.001). Quality of life as assessed by the Dermatology Life Quality Index improved significantly. However, a significant advantage of pimecrolimus over hydrocortisone was not found. <b><i>Conclusion:</i></b> The results suggest that the non-steroid pimecrolimus is an effective alternative for PN treatment.

References

19